Department of Pharmaceutics, School of Pharmacy and Novel Drug Delivery Systems Research Centre, Isfahan University of Medical Sciences, PO Box 81745-359, Isfahan, Iran.
Department of Pharmacology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
Invest New Drugs. 2018 Apr;36(2):206-216. doi: 10.1007/s10637-017-0533-1. Epub 2017 Nov 27.
Purpose Raloxifene (RA) receptors have over-expressed GPER-positive breast cancer tumors. The purpose of this work was to evaluate the antitumor activity and pharmacokinetic behavior of docetaxel (DTX), loaded in RA-targeted nanomicelles, which were designed to overcome a lack of specific distribution and inadequate DTX concentration in tumor tissues, as well as its cytotoxicity and damage to normal tissues. Methods DTX-loaded RA-targeted poly(styrene maleic acid) (SMA)- poly(amide-ether-esterimide)-poly(ethylene glycol) (PAEEI-PEG) nanomicelles were prepared; then, their antitumor activity and survival rate were studied in MC4-L2 tumors induced in BALB/c mice. The pharmacokinetics of DTX-loaded SMA-PAEEI-PEG-RA micelles was also investigated in comparison with free DTX. Results DTX-loaded SMA-PAEEI-PEG-RA micelles inhibited tumor growth considerably and increased animal survival as compared to free DTX and non-targeted micelles. SMA-PAEEIPEG-RA micelles enhanced significantly the area under the curve (AUC0-∞) 1.3 times as compared to free DTX and reduced clearance (CL) from 410.43 ml/kg.h (for free DTX) to 308.8 ml/kg.h (for SMA-PAEEI-PEG-RA micelles). Volume of distribution (Vdss) was also reduced 1.4 times as compared to free DTX. RA-targeted micelles increased tumor inhibition rate (TIR) 1.3 times and median survival time (MST) >1.5 times compared to free DTX. Percentage increase in life span (%ILS) was also enhanced significantly from 41.66% to >83.33% in MC4-L2 tumor-bearing BALB/c mice. Discussion All studies in this work showed the potential of DTX-loaded SMA-PAEEI-PEG-RA micelles in the treatment of GPER-positive receptor breast cancer tumors.
雷洛昔芬(RA)受体在过表达 GPER 阳性乳腺癌肿瘤中表达。本工作的目的是评估载多西紫杉醇(DTX)的 RA 靶向纳米胶束的抗肿瘤活性和药代动力学行为,该纳米胶束旨在克服缺乏特异性分布和肿瘤组织中 DTX 浓度不足的问题,以及其对正常组织的细胞毒性和损伤。方法:制备载多西紫杉醇的 RA 靶向聚(苯乙烯马来酸)(SMA)-聚(酰胺-醚-酯-亚胺)-聚(乙二醇)(PAEEI-PEG)纳米胶束;然后,在 BALB/c 小鼠诱导的 MC4-L2 肿瘤中研究其抗肿瘤活性和存活率。还研究了载多西紫杉醇的 SMA-PAEEI-PEG-RA 胶束与游离多西紫杉醇的药代动力学。结果:与游离多西紫杉醇和非靶向胶束相比,载多西紫杉醇的 SMA-PAEEI-PEG-RA 胶束显著抑制肿瘤生长并提高动物存活率。与游离多西紫杉醇相比,SMA-PAEEIPEG-RA 胶束使 AUC0-∞增加了 1.3 倍,并将清除率(CL)从 410.43 ml/kg.h(游离多西紫杉醇)降低至 308.8 ml/kg.h(SMA-PAEEI-PEG-RA 胶束)。与游离多西紫杉醇相比,分布容积(Vdss)也降低了 1.4 倍。与游离多西紫杉醇相比,RA 靶向胶束使肿瘤抑制率(TIR)提高了 1.3 倍,中位生存时间(MST)提高了 >1.5 倍。在 MC4-L2 荷瘤 BALB/c 小鼠中,生命延长率(%ILS)也从 41.66%显著提高至>83.33%。讨论:本工作中的所有研究均表明,载多西紫杉醇的 SMA-PAEEI-PEG-RA 胶束在治疗 GPER 阳性受体乳腺癌肿瘤方面具有潜力。